Nasdaq exas.

Who is on Exact Sciences's Insider Roster? The list of insiders at Exact Sciences includes Brian Baranick, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, and Sarah Condella. Learn more on insiders at EXAS.

Nasdaq exas. Things To Know About Nasdaq exas.

Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 67.03 +3.03 (+4.73%) At close: 04:00PM EST. 67.10 +0.07 (+0.10%) After hours: 07:58PM...Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new July 8th contracts and identified one put and one call contract of particular interest ...Dec 1, 2023 · Get the latest Exact Sciences Corporation EXAS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 minutes delayed. Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.

Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the average one-year price target for Exact Sciences is 77.82. The forecasts range from a low of 55.55 to a high of $99.75. The ...

Investors in EXACT Sciences Corp. (Symbol: EXAS) saw new options begin trading today, for the December 16th expiration. One of the key data points that goes into the price an option buyer is ...The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...

A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have added about 2.5% in that time frame, underperforming the S&P …WebMADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23 ...EXAS stock, on the other hand, ended the regular session at 51.92, up 16.4%. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.Nov 20, 2023 · Still, here are two companies that could pull it off: Exact Sciences ( EXAS 0.37%) and Airbnb ( ABNB 1.75%). Let's consider why these two innovative businesses could turn $1,000 into $2,000 by the ... EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.

Exact Sciences (NASDAQ:EXAS) stands out as a key player in the field of cancer detection and diagnostics, attracting the attention of investors seeking innovative opportunities.Its recent ...

In recent trading, shares of EXACT Sciences Corp. (Symbol: EXAS) have crossed above the average analyst 12-month target price of $88.50, changing hands for $91.09/share. When a stock reaches the ...

The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...11 Okt 2023 ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ..."Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Exact Sciences's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 28.7% per year. This section of the company report contains some beta features. How Exact Sciences makes and spends money.Exact Sciences Corp (NASDAQ:EXAS) 65.04 Delayed Data As of Nov 29 +0.09 / +0.14% Today’s Change 40.73 Today ||| 52-Week Range 100.77 +31.37% Year-to-Date Quote Profile News Charts Forecasts...

The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities. 2.68%. +0.25 0. ...Exact Sciences' (NASDAQ:EXAS) potential is so misunderstood and undervalued that we believe that EXAS probably has an upside of 100%-300% over the next twelve months based on the prospects of its ...Exact Sciences (NASDAQ: EXAS) is a biotech stock leveraging AI. The company also comprises the largest holding in Cathie Wood’s ARK Genomic Revolution ETF (BATS: ARKG) at 10.38% total weight.Feb 27, 2018 · ADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: Exact Sciences Corp. (Nasdaq:EXAS), a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard Classic, a PGA TOUR Champions event in Tucson, Arizona. Find the latest Earnings Report Date for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Web

Turning to the calls side of the option chain, the call contract at the $39.00 strike price has a current bid of $3.40. If an investor was to purchase shares of EXAS stock at the current price ...

EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. 67.03 USD R +3.03 +4.73%. At close at Dec 1, 16:58 UTC-8. USD. No trades. See on Supercharts. Overview . News . Ideas Financials Technicals Forecast . EXAS news flow. News didn't load. Looks like that didn't go very well. Let's try again.One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -16.81%, and its shares gained 127.30% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...About · Highlight. A leading provider of cancer screening and diagnostic tests · Exchange. NASDAQ · Listing Date. 01/30/2001 · Established Date. 02/10/1995.EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ...Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt Oct 04. Price target increased by 7.0% to US$109 Sep 19. Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13. Executive VP & CFO notifies of intention to sell stockTurning to the calls side of the option chain, the call contract at the $60.00 strike price has a current bid of $4.20. If an investor was to purchase shares of EXAS stock at the current price ...The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.Texas Instruments Incorporated Common Stock (TXN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The ...

Jul 25, 2023 · One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 0.09%, and its shares gained 105.65% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...

One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38.05% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ... Among the largest underlying components of ARKG, in trading today EXACT Sciences Corp. (Symbol: EXAS) is down about 0.3%, Ionis Pharmaceuticals Inc (Symbol: IONS) is up about 3%, and Intellia ...EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 92.96 0.00 0.00%. The 17 analysts offering 1 year price forecasts for EXAS have a max estimate of — and a min estimate of —.MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. Renowned for its development of impactful cancer diagnostic tests, ...Dec 4, 2023 · Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure ... The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ... Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...

Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ... Nov 20, 2023 · Still, here are two companies that could pull it off: Exact Sciences ( EXAS 0.37%) and Airbnb ( ABNB 1.75%). Let's consider why these two innovative businesses could turn $1,000 into $2,000 by the ... After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ...Instagram:https://instagram. brokers to use with mt4cloud fare stockninjatrader futures feesgenesis bankrupt The last time Exact Sciences (NASDAQ: EXAS) announced its quarterly results, revenue increased 64% compared with the prior-year period. It was a different story on the company's bottom line ...Exact Sciences' sales will top $2 billion this year as the business continues to achieve impressive growth. ... NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03. tesla ratingsliberty 1979 dollar Find the latest Institutional Holdings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. corebridge financial inc According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.Dec 2, 2023 · Spyglass Capital Management LLC decreased its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 36.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 661,930 shares of the medical research company's stock after selling 379,516 shares during the quarter.